SuperworthIntelligent Bio Solutions INBS
- Market cap
- $4.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $4.2M
- +38% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −250.4%
Intelligent Bio Solutions trades at 1.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $4.2M over the last twelve months, up 38% on a year earlier.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $796.1K+156% | $764.1K+114% | $823.8K+80% | n/a | $872.3K+10% | $607.5K−21% | $728.9K−12% | $843.9K | $1.1M+28% | $896.8K+48% | $1.1M+46% | $1.1M+36% | |
| Cost of revenue | $563.8K | $564.8K+402% | $645.3K+52% | n/a | $525.5K−7% | $384.4K−32% | $387.5K−40% | $508.3K | $593.5K+13% | $437K+14% | $525.4K+36% | $609.2K+20% |
| Gross profit | $232.3K | $199.2K−18% | $178.5K+440% | n/a | $346.8K+49% | $223.1K+12% | $341.4K+91% | $335.6K | $518.3K+49% | $459.7K+106% | $535.4K+57% | $536.6K+60% |
| R&D | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SG&A | $2.5M+69% | $1.7M−24% | $2.4M+28% | n/a | $1.9M−21% | $1.8M+6% | $2.4M−1% | $2.7M | $2.7M+37% | $2.3M+29% | $2.5M+2% | $3M+10% |
| −$2.5M+107% | −$2M−7% | −$3M−55% | n/a | −$2.7M+8% | −$2.3M+14% | −$2.6M−13% | −$3.1M | −$3M+10% | −$2.6M+16% | −$2.9M+15% | −$4M+28% | |
| Interest expense | $37.4K | $32.5K | $42.7K | n/a | $22.3K−40% | $13.5K−58% | $7.9K−81% | $5.3K | $3.9K−83% | $56.2K+316% | $4.2K−46% | $3.3K−38% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$2.4M+101% | −$2M+368% | −$3M−53% | −$2.8M+5% | −$2.7M+11% | −$2.2M+14% | −$2.5M−15% | −$3.1M+11% | −$3M+11% | −$2.7M+19% | −$2.9M+13% | −$3.9M+27% |
| −$124.80−36% | −$20.70−63% | −$14.30−98% | −$9.10−96% | −$7.00−94% | −$4.96−76% | −$4.41−69% | −$4.41−52% | −$3.50−50% | −$2.82−43% | −$1.80−59% | −$1.56−65% | |
| 19.4K+213% | 95K+1155% | 208K+2151% | 305.1K+2804% | 381.1K+1863% | 453.6K+378% | 577.2K+178% | 700.5K+130% | 854.7K+124% | 950.8K+110% | 1.6M+176% | 2.5M+258% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY20 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20 and Q1 FY21: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Intelligent Bio Solutions' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| INBSIntelligent Bio Solutions | $4.8M | n/m | n/a | 1.1× | +38% | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on Intelligent Bio Solutions
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .